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the deployment of the device in the iliac vein, venous
thrombosis is formed as a result of flow stasis within the
tapered stent-graft. The purposes of this study were (1) to
characterize this deep venous thrombosis model with an
endovascular approach and (2) to evaluate the efficacy of
thrombolytic therapy with this model of acute and chronic
deep venous thrombosis by means of venogram and
intravascular ultrasound (IVUS).
MATERIALS AND METHODS
Animal model. Twenty adult domestic swine each
weighing 45 to 50 kg were used in this study. All animal
procedures and care were performed in accordance with
the Guideline for the Care and Use of Laboratory Animals
(NIH publication No. 80-23, revised 1985).6 Animals
were intravenously given thiopental sodium (10 mg/kg).
Endotracheal intubation was performed, and anesthesia
was maintained with 1% isoflurane. Under sterile condi-
tions, bilateral groin cut downs were performed to
expose the superficial femoral veins. After systemic
heparin infusion (50 U/kg intravenous bolus), 14F
introducer sheaths (Meditech, Watertown, Mass) were
inserted in bilateral superficial femoral veins. Bilateral
antegrade venograms were performed to document the
patency and anatomy of the iliac veins and inferior vena
cava. Animals were divided into five groups (4 per group)
on the basis of the five different time points (1 hour, 
Deep venous thrombosis is estimated to affect 20% to
30% of all major surgical patients and, as a result of pul-
monary embolism, is responsible for more than 60,000
deaths annually in the United States.1,2 Application of
catheter-directed thrombolytic therapy has become an
acceptable form of treatment in selected patients with
deep venous thrombosis.3-5 The rapid progression of
catheter-based intervention has underscored the impor-
tance of an experimental model of deep venous thrombo-
sis in which antithrombotic therapies or endovascular
interventions could be evaluated. In the current study, we
describe an endovascular model of deep venous thrombo-
sis that produces a simple and reliable iliac venous throm-
bosis in pigs. This model uses a stent-graft device that
incorporates a tapered polytetrafluoroethylene (PTFE)
graft attached within a self-expanding nitinol stent. After
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Purpose: The advancement of catheter-based interventions for vascular recanalization has underscored the need for an
experimental animal model of vascular thrombosis that can be used for the evaluation of interventional therapies. In
this model, a porcine model of deep venous thrombosis with a novel endovascular technique was described, and the
efficacy of thrombolytic therapy with urokinase was evaluated.
Methods: An endovascular device that consisted of a tapered polytetrafluoroethylene graft attached within a self-expand-
ing nitinol stent was delivered to bilateral common iliac veins in 20 pigs. Venous thrombosis occurred as a result of
flow stasis created by the intrastent stenosis. Catheter-directed pulse-spray thrombolysis with urokinase (250,000
units) and heparin (5000 IU) was performed on one limb while the contralateral limb received control saline solution.
Thrombolysis was performed in 1 hour (n = 4), 8 hours (n = 4), 3 days (n = 4), 7 days (n = 4), and 14 days (n = 4)
after the stent-graft deployment. Venography and intravascular ultrasound were used to evaluate the efficacy of throm-
bolysis. Light microscopy was used for histologic analysis of the thrombus.
Results: Complete thrombolysis was achieved in groups with deep vein thrombosis that were younger than 1 day.
Angioplasty of the tapered stent-grafts in the completely thrombolysed iliac vein was successful in restoring venous
flow. The efficacy of thrombolysis in 3-day, 7-day, and 14-day groups was 86% ± 7%, 73% ± 13%, and 42% ± 23%,
respectively. The thrombolytic efficacy was enhanced to 92% ± 16% and 86% ± 18% (P < .05) in 3-day and 7-day groups,
respectively, when doses of the pulse-spray thrombolysis were doubled. Increased dosages of the thrombolytic agent,
however, did not significantly enhance the thrombus dissolution in the 14-day group.
Conclusion: The thrombolytic efficacy of urokinase correlated with the chronicity of deep venous thrombosis in our
model. An increased dose of urokinase may be used to enhance the efficacy of thrombolysis in a 1-week-old thrombus.
(J Vasc Surg 2001;33:621-7.)
8 hours, 3 days, 7 days, and 14 days) in which throm-
bolysis was performed after the stent-graft deployment.
The iliac venous thrombus was formed because of flow
stasis created by the tapered stent-graft device in the iliac
vein. Animals in the 1-hour and 8-hour groups under-
went mechanical ventilation until thrombolysis was com-
pleted. Animals in the 3-, 7-, and 14-day groups were
allowed to be extubated and recovered after the stent-
graft deployment. These animals were anesthetized and
reintubated in respective time points followed by bilat-
eral groin cut down and introducer sheath placement for
thrombolytic therapy. Each animal served as its own con-
trol as urokinase and heparin were pulse-sprayed in one
iliac vein while the contralateral vein received control
saline pulse-spray.
The stent-graft model for iliac vein thrombosis.
The stent-graft device used to induce venous thrombosis
consist of a tapered 4- to 14-mm PTFE graft (expanded
polytetrafluoroethylene [ePTFE]; W. L. Gore, Inc,
Tempe, Ariz) attached in an inverted fashion to a 14-mm
× 4-cm self-expandable nitinol Symphony stent (Boston
Scientific Corp, Watertown, Mass). The Symphony stent
was first deployed on a sterile operating room table. The
outer wrapping layer of a 4-mm ePTFE graft was carefully
peeled away, followed by the insertion of a 14-mm angio-
plasty balloon (Meditech) inside the graft. The balloon
was inflated to a fully expanded state, which also expanded
the graft to the similar diameter. By balloon expansion of
a 4-mm diameter graft, it created a tapered segment of 14-
to 4-mm ePTFE grafts. The graft was trimmed to a 5-cm
segment, leaving the tapered region in the center of this 5-
cm graft segment. The expanded end of the graft was gen-
tly fitted over the stent 1 cm in length and attached to
each individual strut with interrupted 5-0 polyprolene
sutures (Ethicon, Inc, Somerville, NJ) (Fig 1). Next, the
tapered end of the graft was inverted inside the stent to
produce a 4-mm stenosis within the stent lumen, thus cre-
ating a 4-mm intrastent stenosis (Fig 2). Next, the device
was crimped and fitted inside of a cut 12F introducer
sheath tubing that was inserted into the 14F introducer
sheath in the common femoral vein to deploy the tapered
stent-graft device in the iliac vein. A 12F sheath dilator
was cut to form a blunt end and inserted into the intro-
ducer sheath to advance the stent-graft device forward.
Once the stent-graft device was advanced to 2 cm below
the iliac bifurcation in the proximal iliac vein as confirmed
with fluoroscopic examination, the introducer sheath was
slowly withdrawn, while the blunt sheath dilator was kept
in place, which completed the deployment of stent-graft in
the proximal iliac vein (Fig 2). Next, the blunt sheath dila-
tor was removed from the introducer sheath, and the
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Fig 1. A tapered PTFE graft was attached to a 14-mm self-
expanding Symphony stent with interrupted 5-0 polyprolene
sutures. 
Fig 2. The tapered graft was next inverted within the stent, and
the stent-graft was deployed in the common iliac vein, which pro-
duced venous thrombus because of flow stasis. A Greenfield filter
was placed in the infrarenal vena cava to prevent pulmonary
embolism. Arrow indicates the location of the symphony stent
containing the tapered PTFE graft.
venogram was performed to assess the thrombus forma-
tion (Fig 3).
Inferior vena cava filter placement. Before the
deployment of the stent-graft device, a Greenfield caval filter
(Meditech) was deployed in the infrarenal vena cava in each
animal. The filter was positioned so that the lowest strut of
filter was 2 cm above the iliac bifurcation. The purpose of
the inferior vena cava filter was to prevent possible pul-
monary embolism due to iliac vein thrombus dislodgement. 
Thrombolytic therapy. After the deployment of the
tapered stent-graft device in the iliac vein, venous throm-
bus was formed as a result of flow stasis within the
intrastent stenosis. The iliac venous thrombosis was noted
above and below the tapered stent-graft device, as con-
firmed with IVUS, before thrombolytic therapy.
Thrombolytic therapy with urokinase (250,000 units;
Abbott Laboratories, North Chicago, Ill) and heparin
(5000 IU) was administered by means of a pulse-spray
technique at 1 hour, 8 hours, 3 days, 7 days, or 14 days
after the stent-graft deployment. A 0.035-in Bentson
guidewire (Meditech) was inserted through the introducer
sheath in the femoral vein to cannulate the stent-graft
device in the iliac vein. A 6F Mewissen infusion catheter
(Meadox, Oakland, NJ) was placed over the guidewire and
positioned across the tapered stent-graft, such that pulse-
sprayed urokinase was administered to iliac vein thrombus
both above and below the stent-graft device. We mixed
250,000 IU of urokinase and 1000 units of heparin in 10
mL of sterile water and infused with a pulse-spray tech-
nique previously described by Valji and Bookstein.7 The
thrombolytic agent was manually pulsed in a 0.2-mL
aliquot every 30 seconds with a tuberculin syringe. A sec-
ond Mewissen catheter was similarly placed over a Bentson
guidewire in the contralateral iliac vein, and control saline
solution was pulse-sprayed in a similar fashion. IVUS was
used 30 minutes after the completion of the pulse-spray
thrombolysis to assess the degree of thrombolytic efficacy.
In the event that residual thrombus was detected after the
initial urokinase and heparin infusion, a second dose of
urokinase and heparin (250,000 units and 5000 IU,
respectively) was administered with pulse-spray. Antegrade
iliac venogram and IVUS were performed after urokinase
infusion to assess the efficacy of the thrombolytic therapy.
In iliac vein that was amenable to complete thrombolysis,
balloon angioplasty with a 14-mm balloon (Meditech) was
performed to dilate the tapered stent-graft to restore the
venous flow (Fig 4). 
Intravascular ultrasound. A 3.5F, 20-MHz IVUS
catheter was inserted over the guidewire with a ClearView
Ultra Intravascular Ultrasound System (Meadox). Before
the thrombolytic therapy, IVUS was used to assess the iliac
venous thrombus. The IVUS catheter was first inserted in
the proximal iliac vein beyond the distal portion of the
stent-graft, and five different images were obtained in the
proximal 2 cm of each iliac vein for thrombus measure-
ment. After thrombolysis, the IVUS catheter was again
positioned within the proximal 2 cm of the iliac vein to
obtain five different images for residual thrombus mea-
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surement. Spot fluoroscopic image was used to confirm
the location of the IVUS transducer within the proximal
iliac vein. The luminal dimensions before urokinase (BU)
and after urokinase (AU) thrombolysis were traced on the
IVUS image with a tracking device, which allowed calcu-
lation of a cross-sectional area:
Efficacy of thrombolytic therapy (%) = 1 – (AreaAU/
AreaBU) × 100
Histology. Bilateral common iliac veins were harvested
and fixed in formalin after the completion of thrombolysis.
After the iliac vein harvest, the stent-graft device was care-
fully removed. Iliac vein segments outside and proximal to
the stent-graft placement site were analyzed. After dehydra-
tion in graded alcohol, hematoxylin and eosin staining was
performed in these specimens. Multiple cross sections in the
common iliac veins were made to examine the thrombus
composition with light microscopy. Immunohistochemical
analysis with antiplatelet and antifibrin antibodies (Sigma,
St Louis, Mo) was also performed to detect the presence of
platelet and fibrin.
Statistical analysis. Data are expressed as means ± SD.
The efficacy of thrombolysis over different groups was ana-
lyzed between urokinase versus saline control with the
Student t test and analysis of variance techniques. Signi-
ficance was considered when the P value was less than .05. 
Fig 3. Venous thrombus occurred as a result of flow stasis cre-
ated by tapered stent-graft 3 days after deployment. 
RESULTS
All 20 animals survived the endovascular procedures.
The stent-graft was successfully deployed in all animals,
and no complications were noted as a result of iliac vein
thrombosis. Iliac venogram showed that iliac vein throm-
bus occurred in 42 ± 6 minutes after the stent-graft device
deployment. 
Thrombolytic therapy. The thrombolytic efficacy
and the thrombus areas calculated with IVUS are summa-
rized in the Table. Thrombolytic therapy with urokinase
and heparin was successful in dissolving all the iliac venous
thrombus in the 1-hour and 8-hour groups, whereas the
control saline pulse spray showed minimal thrombolytic
effects in these two groups (100% vs 12% ± 4% at 1 hour,
and 100% vs 8% ± 3% at 8 hours, P < .01). The times of
thrombus dissolution in the 1-hour and 8-hour groups
were 6 ± 3 minutes and 8 ± 4 minutes, respectively. Balloon
angioplasty was successful in dilating the tapered stent-
graft in the 1-hour and 8-hour groups, which restored the
normal blood flow in the iliac veins angiographically (Fig
5). Although the thrombolytic efficacy was decreased as
the age of iliac vein thrombus increased, urokinase and
heparin remained more successful in dissolving the iliac
venous thrombus compared with the control pulse-spray in
the 3-day, 7-day, and 14-day groups (86% ± 7% vs 10% ±
4% at 3 days; 73% ± 13% vs 14% ± 6% at 7 days; 42% ± 23%
vs 11% ± 5% at 14 days; P < .01) (Table).
In the 3-day, 7-day, and 14-day groups, residual
venous thrombi were detected after the initial pulse-spray
thrombolysis in the iliac veins. An additional dose of
urokinase (250,000 units) and heparin (5000 IU) was
pulse-sprayed 10 minutes after the initial thrombolytic
therapy. The thrombolytic efficacy was enhanced to 92% ±
16% and 86% ± 18% in 3-day and 7-day groups, respec-
tively (P < .05). In the 14-day group, however, the
increased dosage of the thrombolytic agent did not
enhance the thrombus dissolution. Although no animals
in the study died unexpectedly because of a theoretical risk
of pulmonary embolism, postmortem analysis showed that
18 animals (90%) had venous thrombus trapped in the
caval filter.
Light microscopy. Histologic analysis of the venous
thrombus revealed presence of abundant red blood cells in
the fibrin mesh in all animal groups. Thrombus adherence
to the intima was present in 15 specimens (75%).
Immunohistologic analysis with antifibrin antibody
revealed an abundance of fibrin within the thrombus in all
animal groups (100%). When examined with antiplatelet
antibody, platelet aggregates were seen in 3 specimens
(75%) in the 14-day group, 2 specimens (50%) in the 7-
day group, and 2 specimens (50%) in the 3-day group. No
platelet aggregation was seen in either the 1-hour or 8-
hour group.
DISCUSSION
Despite the remarkable improvement in the pharma-
cologic prophylaxis in past decades, venous thromboem-
bolism continues to be a significant cause of morbidity and
mortality in this country. Pharmacologic dissolution of an
established venous thrombosis has become an important
therapeutic approach in selected patients encountered in
clinical practice.3 Catheter-directed intravascular infusion
of thrombolytic agents, such as streptokinase, urokinase,
or tissue plasminogen activator, activates the fibrinolytic
cascade and is effective in restoring blood flow in occluded
vessels.3,8,9 The advancement of the catheter-based inter-
vention has underscored the importance of an experimen-
tal model of deep venous thrombosis in which
antithrombotic therapies or endovascular interventions
could be evaluated. 
The current study demonstrated a deep venous throm-
bosis model in the porcine iliac vein and evaluated the effi-
cacy of the thrombolytic agent, urokinase, by means of
catheter-directed pulse-spray infusion. The thrombolytic
potency of urokinase correlated with the age of the iliac
venous thrombus as a freshly formed thrombus younger
than 1 day was amenable to complete thrombolytic disso-
lution. As the age of the venous thrombus increased, the
efficacy of urokinase correspondingly decreased. In our
model, additional pulse-spray of urokinase further
enhanced the thrombolytic efficacy of venous thrombus
aged 3 days and 7 days. Although the 14-day-old venous
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IVUS evaluation of thrombus areas and thrombolytic efficacy after either urokinase* or saline pulse-spray in the iliac vein
Group Pulse-spray agent Prethrombolysis thrombus area (mm2) Postthrombolysis thrombus area (mm2) Thrombolytic efficacy (%)
1 h Urokinase 73.4 ± 7.4 0 100
Saline 75.8 ± 12.9 68.8 ± 9.7 12 ± 4†
8 h Urokinase 71.4 ± 7.4 0 100
Saline 78.2 ± 11.8 72.2 ± 18.5 8 ± 3†
3 d Urokinase 82.9 ± 13.5 10.2 ± 3.7 86 ± 7
Saline 71.4 ± 6.4 64.6 ± 8.2 10 ± 4†
7 d Urokinase 77.8 ± 8.9 21.9 ± 6.4 73 ± 13‡
Saline 75.9 ± 10.6 64.8 ± 12.5 14 ± 6†
14 d Urokinase 72.7 ± 11.5 42.2 ± 9.5 42 ± 23‡
Saline 74.2 ± 9.4 66.3 ± 7.4 11 ± 5†
*250,000 IU.
†P < .01 compared with urokinase treatment in the respective group.
‡P < .05 compared with the 1-hour urokinase pulse-spray group.
thrombus showed a partial dissolution after the initial
thrombolysis, additional thrombus dissolution could not
be achieved with the additional thrombolytic therapy.
The findings from our study were in agreement with
the clinical observation that acute venous thrombus is
highly amenable to thrombolysis, whereas chronic venous
thrombus is more resistant to thrombolytic therapy. Several
clinical studies in which catheter-directed thrombolysis was
used have demonstrated high success rates in the treatment
of acute deep venous thrombus, which ranged between
50% and 80%.10-12 The mechanism by which chronic
thrombus becomes resistant to thrombolytic therapy
remains unclear. Jang et al13 postulated a possible mecha-
nism in that chronic thrombus may become more struc-
turally organized with high-platelet composition, as
opposed to fibrin-rich and platelet-poor composition,
which occurred in acute thrombus. A similar finding was
noted in our study in which increased platelet aggregates
were observed in the 14-day venous thrombosis group
compared with either the 1-hour or 8-hour group.
Platelet-rich thrombus not only has higher concentrations
of proaggregatory mediators, such as adenosine diphos-
phate, serotonin, and thromboxane A2, but also contains
increased antifibrinolytic mediators, including plasminogen
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activator inhibitor and α2-antiplasmin.13 Consequently, the
increased antifibrinolytic and proaggregatory activities
make these thrombi more resistant to either endogenous
fibrinolysis or exogenous thrombolytic therapy.
Various venous experimental models to induce venous
thrombosis have been described in the literature. These
thrombosis models use a variety of approaches, which
include electrical injury, devascularization, photochemical
reaction, and intraluminal foreign body placement.14-17 In
our model, the causative factor of the venous thrombus
formation is due to the flow stasis created by the stenosis
within the tapered stent-graft device. The unique feature
of our model is the incorporation of a tapered graft
attached within a self-expanding nitinol stent. The intralu-
minal stenosis creates a stagnant flow within the venous
circulation, which promotes thrombus formation. The
physiologic significance of the flow stasis leading to
venous thrombosis as a result of the intraluminal stenosis
has been confirmed previously.18 The deployment of a 14-
mm stent that contained a 4-mm tapered graft reliably
produces venous thrombus in animals used in our study.
The consistency of venous thrombus formation after the
tapered stent-graft deployment allows an accurate deter-
mination of the age of the thrombus when thrombolytic
therapies are to be evaluated.
Fig 5. Complete venogram demonstrated restoration of iliac
venous flow after both thrombolysis and balloon angioplasty.
Fig 4. After 250,000 IU of urokinase and 1000 units of heparin
pulse-spray infusion, complete thrombolysis was achieved in the
1-hour and 8-hour groups. Balloon angioplasty was performed to
eliminate stenosis created by tapered graft.
A vena caval filter can be placed in our animal model
to prevent potential pulmonary embolism. In contrast to
systemic thrombolytic therapy, which infuses the agent at
a constant rate, we evaluated the pulse-spray pharmaco-
mechanical thrombolysis in our study. This approach pro-
vides a high-pressure injection through a multisidehole
catheter in a repeated small volume. An advantage of
pulse-spray pharmacomechanical thrombolysis includes
enhanced thrombus maceration as a result of high-pres-
sure injection of the lytic agents. Furthermore, the
catheter-directed thrombolytic infusion increases the con-
tact area between the thrombus and the lytic agents.
Finally, the concentrated volume of pulse-spray infusion
increases the rate of thrombus dissolution, while minimiz-
ing the overall volume of lytic agent used.19 The pulse-
spray pharmacomechanical thrombolysis may be
associated with an increased risk of inadvertent dislodge-
ment of iliac venous thrombus in our model. Postmortem
analysis showed that 90% of caval filters trapped large
venous thrombus, which protected a hypothetical risk of
pulmonary embolism associated with pulse-spray throm-
bolytic therapy.
One observation noted from this study was that despite
the intraluminal stenosis in the iliac vein, which promoted
thrombus formation, complete occlusion of the iliac vein
never occurred. One possible explanation was that flow sta-
sis was responsible for the larger size of venous thrombi
because of sluggish flow, which allowed thrombin to accu-
mulate to high levels and, therefore, trapped more red
blood cells in the fibrin mesh. The histologic staining of
the iliac thrombus demonstrated a mixture of concentra-
tions of thrombin and red blood cells with a paucity of
platelet aggregates. The minimal platelet deposition along
the venous wall was not a surprising finding considering
that the iliac veins had not been previously traumatized.
Presumably, there was less activation of platelets and of the
intrinsic and extrinsic clotting pathways, which typically
occur with exposure of an injured vessel wall to circulating
blood components. This condition may allow a more accu-
rate assessment of changes in thrombus burden and subse-
quent evaluation of thrombolytic therapy because ongoing
thrombus propagation may have been minimized. The
thrombus morphology was similar in its composition com-
pared with other animal models that used occluding
devices to cause stasis.20,21 In addition, our finding was
supported by a previous study on the structural analysis of
thrombi that demonstrated that thrombus with a mixed
type of thrombin and red blood cells is more commonly
found in venous thrombosis.22 These thrombi were more
likely to undergo a spontaneous thrombolysis, which was
initiated by plasmin and other proteolytic cascades trig-
gered by inflammatory cells that were present in the initial
phase of thrombus formation. Therefore, deep venous
thrombosis was more likely to become partially occluded
because of the presence of spontaneous thrombolysis.
The tapered stent-graft model has also been used
recently in our laboratory to develop an iliac artery throm-
bosis model, which consistently produced complete arte-
rial occlusion after the stent-graft deployment.23 The
endothelium lining the initimal surface may account for
the difference between venous and arterial thrombotic
reaction. For instance, more tissue plasminogen activators
have been secreted by the venous endothelial cells than the
arterial endothelial cells. In addition, plasmin content is
higher in venous circulation than in arterial circulation.24
The increased plasmin content and tissue plasminogen
activators may in part explain why venous thrombosis
remained partially recanalized.25
The efficacy of thrombolytic therapy was assessed with
venography and IVUS in our study. Although venography
provided useful information regarding the degree of recan-
nalization after thrombolysis, it is less accurate in detecting
the presence of residual thrombus. Because the venography
displayed images by creating a two-dimensional silhouette
of a vessel, a small residual thrombus may be undetected if
the contrast filled the surrounding lumen of the vessel.26
By contrast, previous studies have demonstrated the accu-
racy of IVUS to assess alterations in the luminal area and
the integrity of the intimal surface.27 The use of IVUS,
therefore, provided an essential tool in studying the degree
of luminal narrowing and in detecting any residual throm-
bus after thrombolysis.
The porcine model was chosen in our study because of
the large size of the iliac vein, which is similar to the
human venous system. This large vessel caliber permits the
utility of the same thrombolytic catheters, guidewires, and
stents as those used in the clinical interventions.
Furthermore, the vascular wall response in pigs to athero-
genic stimuli and endovascular treatment is similar to the
response of human arteries.28,29 Pigs exhibit a higher
propensity to induce arterial thrombosis, however, pre-
sumably because of a decrease of production of prostacy-
clin by the arterial wall.30 
In conclusion, we described in this study a porcine
model of venous thrombosis with an endovascular
approach that induces thrombus formation by means of
intraluminal stenosis. The model is simple to create and
reliably produces venous thrombosis. The thrombolytic
efficacy of urokinase correlated with the chronicity of deep
vein thrombosis in our model. This model may provide a
useful tool for further investigation of antithrombotic
therapy in venous thromboembolism.
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